MA41134A - Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales - Google Patents

Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales

Info

Publication number
MA41134A
MA41134A MA041134A MA41134A MA41134A MA 41134 A MA41134 A MA 41134A MA 041134 A MA041134 A MA 041134A MA 41134 A MA41134 A MA 41134A MA 41134 A MA41134 A MA 41134A
Authority
MA
Morocco
Prior art keywords
prophylaxis
treatment
viral infections
thiazolo
pyrimidine
Prior art date
Application number
MA041134A
Other languages
English (en)
Other versions
MA41134B1 (fr
Inventor
Dongdong Chen
Song Feng
Lu Gao
Chao Li
Baoxia Wang
Lisha Wang
Hongying Yun
Xiufang Zheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA41134A publication Critical patent/MA41134A/fr
Publication of MA41134B1 publication Critical patent/MA41134B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (i), dans laquelle r1, r2 et r3 sont tels que décrits ici, et leurs promédicaments ou leur sel, énantiomère ou diastéréoisomère pharmaceutiquement acceptables de ceux-ci, des compositions comprenant les composés ainsi que des procédés d'utilisation des composés comme agonistes de tlr7 pour le traitement et la prophylaxie d'infections virales.
MA41134A 2014-12-08 2015-12-03 Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales MA41134B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014093224 2014-12-08
CN2015086987 2015-08-14
PCT/EP2015/078439 WO2016091698A1 (fr) 2014-12-08 2015-12-03 Composés 5-amino-6h-thiazolo [4,5-d]pour le traitement et la prophylaxide d'infections virales

Publications (2)

Publication Number Publication Date
MA41134A true MA41134A (fr) 2017-10-18
MA41134B1 MA41134B1 (fr) 2021-03-31

Family

ID=54771116

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41134A MA41134B1 (fr) 2014-12-08 2015-12-03 Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales

Country Status (31)

Country Link
US (4) US9441008B2 (fr)
EP (1) EP3230298B1 (fr)
JP (1) JP6817217B2 (fr)
KR (2) KR102557560B1 (fr)
CN (2) CN106164079B (fr)
AU (1) AU2015359692B2 (fr)
BR (1) BR112017011941B1 (fr)
CA (1) CA2963717C (fr)
CL (1) CL2017001426A1 (fr)
CR (1) CR20170237A (fr)
DK (1) DK3230298T3 (fr)
EA (1) EA038744B1 (fr)
ES (1) ES2864223T3 (fr)
HK (1) HK1245764A1 (fr)
HR (1) HRP20210454T1 (fr)
HU (1) HUE053704T2 (fr)
IL (1) IL251285B (fr)
LT (1) LT3230298T (fr)
MA (1) MA41134B1 (fr)
MX (1) MX2017007044A (fr)
MY (1) MY194002A (fr)
PE (1) PE20170679A1 (fr)
PH (1) PH12017501061A1 (fr)
PL (1) PL3230298T3 (fr)
PT (1) PT3230298T (fr)
RS (1) RS61612B1 (fr)
SG (1) SG11201704512PA (fr)
SI (1) SI3230298T1 (fr)
TW (1) TWI733656B (fr)
UA (1) UA124184C2 (fr)
WO (1) WO2016091698A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3230298T1 (sl) * 2014-12-08 2021-04-30 F. Hoffmann-La Roche Ag Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom
MX370769B (es) * 2015-03-16 2019-12-20 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
WO2016180743A1 (fr) * 2015-05-12 2016-11-17 F. Hoffmann-La Roche Ag Nouvelle aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale
CN107820498B (zh) 2015-06-30 2020-06-19 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3526323B1 (fr) 2016-10-14 2023-03-29 Precision Biosciences, Inc. Méganucléases génétiquement modifiées spécifiques pour des séquences de reconnaissance dans le génome du virus de l'hépatite b
JP7201598B2 (ja) 2017-01-06 2023-01-10 エフ．ホフマン－ラ ロシュ アーゲー ３位置換５－アミノ－６Ｈ－チアゾロ［４，５－ｄ］ピリミジン－２，７－ジオン化合物の製造法
KR20230141899A (ko) * 2017-01-06 2023-10-10 에프. 호프만-라 로슈 아게 [(1S)-1-[(2S,4R,5R)-5-(5-아미노-2-옥소-티아졸로[4,5-d]피리미딘-3-일)-4-하이드록시-테트라하이드로퓨란-2-일]프로필]아세테이트의 고체 형태
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
AU2018385693A1 (en) 2017-12-15 2020-06-18 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
EP3728283B1 (fr) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting
PL3759109T3 (pl) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Podstawione związki pirolizyny jako inhibitory replikacji hbv
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
PE20211598A1 (es) * 2018-05-25 2021-08-18 Primmune Therapeutics Inc Agonistas de tlr7
WO2020028097A1 (fr) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092621A1 (fr) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composés de 6-azabenzimidazole substitués en tant qu'inhibiteurs de hpk1
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
CN114341185A (zh) 2019-06-19 2022-04-12 希沃尔拜克治疗公司 抗间皮素抗体及其免疫缀合物
US11339159B2 (en) * 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
AU2020357502A1 (en) 2019-09-30 2022-05-19 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
BR112022010165A2 (pt) 2019-11-26 2022-08-09 Primmune Therapeutics Inc Agonistas de tlr7
EP4069729A1 (fr) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Méganucléases modifiées optimisées ayant une spécificité pour une séquence de reconnaissance dans un génome du virus de l'hépatite b
AU2020415322A1 (en) 2019-12-24 2022-06-16 F. Hoffmann-La Roche Ag Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
KR20220119616A (ko) 2019-12-24 2022-08-30 에프. 호프만-라 로슈 아게 Tlr7 효현제를 이용하여 바이러스 감염을 치료하는 방법
WO2021130266A1 (fr) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Association pharmaceutique d'un oligonucléotide thérapeutique ciblant le vhb et un agoniste de tlr7 pour le traitement du vhb
AU2021231160A1 (en) 2020-03-02 2022-09-22 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2021188959A1 (fr) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Promédicaments de nucléosides de 4'-c-substitué-2-halo-2'-désoxyadénosine et leurs procédés de fabrication et d'utilisation
CN116056725A (zh) 2020-08-04 2023-05-02 蛋白科技先鋒 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
EP4194008A1 (fr) 2020-08-04 2023-06-14 Progeneer Inc. Ensemble adjuvant à action cinétique
WO2022029209A1 (fr) 2020-08-05 2022-02-10 F. Hoffmann-La Roche Ag Traitement par oligonucléotides des patients atteints d'hépatite b
CA3215049A1 (fr) 2021-04-10 2022-10-13 Baiteng ZHAO Agents de liaison a folr1, conjugues de ceux-ci et leurs procedes d'utilisation
WO2022226317A1 (fr) 2021-04-23 2022-10-27 Profoundbio Us Co. Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation
KR20240006683A (ko) 2021-05-13 2024-01-15 길리애드 사이언시즈, 인코포레이티드 TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023083906A2 (fr) 2021-11-11 2023-05-19 F. Hoffmann-La Roche Ag Combinaisons pharmaceutiques pour le traitement du vhb

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
EP1072607A3 (fr) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Analogues de nucléosides-L-purine et leurs utilisations
ATE271063T1 (de) 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
WO2005016235A2 (fr) 2003-04-14 2005-02-24 The Regents Of The University Of California Utilisation combinee d'inhibiteurs de l'inosine monophosphate deshydrogenase (impdh) et d'agonistes du toll-like recepteur
EP1667694B1 (fr) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Ligands tlr7 destines au traitement du virus de l'hepatite c
CN101212968B (zh) * 2004-12-17 2011-11-16 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
EP1824482B1 (fr) * 2004-12-17 2014-02-12 Anadys Pharmaceuticals, Inc. Composes de 3h-oxazolo et 3h-thiazolo [4,5-d]pyrimidine-2-one disubstitues en 3, 5 et trisubstitues en 3, 5, 7 et promedicaments associes
ES2345904T3 (es) 2005-11-21 2010-10-05 Anadys Pharmaceuticals, Inc. Proceso para preparar 5-amino-3h-tiazolo(4,5-d)pirimidin-2-ona.
AR061024A1 (es) 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
AU2007260828B2 (en) * 2006-06-22 2013-03-07 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3'-deoxy-beta-D-ribofuranosyl)-thiazolo[4,5-d] pyrimidin-2,7-dione
DE602007012881D1 (en) 2006-07-18 2011-04-14 Anadys Pharmaceuticals Inc Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
BRPI0717741A2 (pt) 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
WO2009026292A1 (fr) * 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Procédés de dosage pour le traitement de pathologies
SI3230298T1 (sl) * 2014-12-08 2021-04-30 F. Hoffmann-La Roche Ag Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom
MX370769B (es) 2015-03-16 2019-12-20 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
WO2016180743A1 (fr) 2015-05-12 2016-11-17 F. Hoffmann-La Roche Ag Nouvelle aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale
CN107820498B (zh) 2015-06-30 2020-06-19 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮

Also Published As

Publication number Publication date
TWI733656B (zh) 2021-07-21
LT3230298T (lt) 2021-04-12
EP3230298B1 (fr) 2021-01-20
NZ730398A (en) 2023-12-22
CR20170237A (es) 2017-08-10
EP3230298A1 (fr) 2017-10-18
PE20170679A1 (es) 2017-05-22
SI3230298T1 (sl) 2021-04-30
ES2864223T3 (es) 2021-10-13
CN106164079A (zh) 2016-11-23
EA038744B1 (ru) 2021-10-13
KR20170088869A (ko) 2017-08-02
JP2017537158A (ja) 2017-12-14
CN107445980B (zh) 2021-04-20
CA2963717A1 (fr) 2016-06-16
CL2017001426A1 (es) 2018-02-16
JP6817217B2 (ja) 2021-01-20
WO2016091698A1 (fr) 2016-06-16
BR112017011941A2 (pt) 2017-12-26
PH12017501061B1 (en) 2017-12-11
US11180525B2 (en) 2021-11-23
CN106164079B (zh) 2017-10-20
US10618929B2 (en) 2020-04-14
EA201791011A1 (ru) 2017-10-31
IL251285B (en) 2021-10-31
KR102557560B1 (ko) 2023-07-20
HUE053704T2 (hu) 2021-07-28
US20190169222A1 (en) 2019-06-06
US20160326209A1 (en) 2016-11-10
US20200239514A1 (en) 2020-07-30
AU2015359692B2 (en) 2020-07-09
PT3230298T (pt) 2021-03-15
US9441008B2 (en) 2016-09-13
HK1245764A1 (zh) 2018-08-31
TW201629072A (zh) 2016-08-16
CN107445980A (zh) 2017-12-08
PH12017501061A1 (en) 2017-12-11
PL3230298T3 (pl) 2021-06-14
MY194002A (en) 2022-11-07
US20160194350A1 (en) 2016-07-07
RS61612B1 (sr) 2021-04-29
DK3230298T3 (da) 2021-03-22
MX2017007044A (es) 2017-11-08
SG11201704512PA (en) 2017-07-28
BR112017011941B1 (pt) 2023-02-28
IL251285A0 (en) 2017-05-29
US10040815B2 (en) 2018-08-07
MA41134B1 (fr) 2021-03-31
HRP20210454T1 (hr) 2021-04-30
KR20230113824A (ko) 2023-08-01
UA124184C2 (uk) 2021-08-04
CA2963717C (fr) 2023-10-10
AU2015359692A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA46038A (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA37942B1 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
EP4374858A3 (fr) Dérivés de la benzimidazolone en tant qu'inhibiteurs du récepteur bcl6
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
EP4371562A3 (fr) Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
NZ746906A (en) Oxaborole esters and uses thereof
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA42972B1 (fr) Nouveaux composés sulfonimidoylpurinone et dérivés pour le traitement et la prophylaxie d'infection virale
MX2022005912A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria.
MA38591A1 (fr) Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA35887B1 (fr) Nouveaux dérivés morpholynyle utiles comme inhibiteurs de mogat-2
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam